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Background: Idiotypes (Id) are antigenic determinants localized in variable (V) regions
of Ig. Id-speciﬁc T and B cells (antibodies) play a role in immunotherapy of Id+ tumors.
However, vaccine strategies that enhance Id-speciﬁc responses are needed. Methods:
Id+ single-chain fragment variable (scFv) from multiple myelomas and B cell lymphomas
were prepared in a fusion format that bivalently target surface molecules on antigen-
presenting cells (APC). APC-speciﬁc targeting units were either scFv from APC-speciﬁc
mAb (anti-MHC II, anti-CD40) or chemokines (MIP-1α, RANTES). Homodimeric Id-vaccines
were injected intramuscularly or intradermally as plasmids in mice, combined with elec-
troporation. Results: (i) Transfected cells secreted plasmid-encoded Id+ fusion proteins
to extracellular ﬂuid followed by binding of vaccine molecules to APC. (ii) Targeted vac-
cine molecules increased Id-speciﬁc B andT cell responses. (iii) Bivalency and xenogeneic
sequences both contributed to enhanced responses. (iv)Targeted Id DNA vaccines induced
tumor resistance against challenges with Id+ tumors. (v) Human MIP-1α targeting units
enhanced Id-speciﬁc responses in mice, due to a cross reaction with murine chemokine
receptors. Thus, targeted vaccines designed for humans can be quality tested in mice.
(vi) Human Id+ scFv from four multiple myeloma patients were inserted into the vaccine
format andwere successfully tested inmice. (vii) HumanMIP-1α vaccine proteins enhanced
human T cell responses in vitro. (viii) A hypothetical model for how the APC-targeted vac-
cine molecules enhance Id-speciﬁcT and B cells is presented. Conclusion:Targeted DNA
Id-vaccines show promising results in preclinical studies, paving the way for testing in
patients.
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INDUCTION OF ANTI-Id ANTIBODIES TO SYNGENEIC Ig
In their classical studies, Oudin and Michel (1963) and Kunkel
et al. (1963) immunized rabbits with human Ig and observed
that the rabbits made antibodies speciﬁc for the injected Ig.
The antigen recognized by the rabbit antibodies was called idio-
type (Id). In hindsight, these observations are perhaps not so
surprising since xenogeneic Ig variable (V) regions, where the
Id is located, are expected to be immunogenic when crossing
species barriers, due to inter species sequence differences between
V regions.
Maybe more surprising, Eisen and colleagues demonstrated
that immunization with amonoclonal Ig,myeloma proteinM315,
induced anti-Id antibodies even in syngeneic BALB/c mice (Siris-
inha and Eisen, 1971). This important ﬁnding indicated that Ig
V regions can be autoimmunogenic, as later formally demon-
strated by Rodkey (1974). In order to elicit syngeneic anti-Id
antibodies, Eisen and colleagues used an extensive immuniza-
tion schedule, starting with M315 in complete Freund’s adjuvant.
Thus, syngeneic Ig appeared to be weak autoantigens in terms of
eliciting anti-Id antibodies (Sirisinha and Eisen, 1971). Moreover,
immunogenicity of various monoclonal Ig differed. In particular,
an abundant Ig with germline-encoded V regions (T15) failed
to induce anti-Id antibodies, presumably due to self-tolerance
(Sakato and Eisen, 1975). Hence, somatic mutations and/orV(D)J
junctional diversity appear to be required for sufﬁcient “foreign-
ness” of Id to be immunogenic in an autologous setting. These
seminal observations of Sirisinha and Eisen (1971) have later
been repeated with a large number of Igs with essentially similar
results.
INDUCTION OF ANTI-Id ANTIBODIES IS DEPENDENT ON
Id-SPECIFIC T CELLS
T cell deﬁcient mice, either nude mice (Schrater et al., 1979) or
neonatally thymectomizedmice (Cosenza et al., 1977), do not pro-
duce anti-Id antibodies upon immunization with Ig. Thus, Ig is a
T dependent antigen like most protein antigens. Consistent with
this, Janeway et al. (1975) and Jorgensen and Hannestad (1977)
found that immunization of mice with Ig induced Id-speciﬁc T
cells that could help secondary hapten-speciﬁc B cells in adoptive
cell transfer experiments performed essentially ad modumMitchi-
son (1971) and Rajewsky (1971). Jorgensen and Hannestad (1980,
1982) further found that elicitationof Id-speciﬁcT cells speciﬁc for
the M315 monoclonal Ig was under the inﬂuence of MHC-linked
immune response (Ir) genes. The Id determinant was localized
to complementarity determining region (CDR) 3 of the λ2315 Ig
light (L) chain (Jorgensen et al., 1983; Bogen et al., 1985). Bogen
et al. (1986a,b) and Bogen and Lambris (1989) cloned T cells spe-
ciﬁc for this particular Id (λ2315)-determinant and showed that
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these T cells were CD4+ and recognized aa 91–101 of the λ2315
L chain presented on the MHC class II molecule I-Ed in BALB/c
mice. Moreover, it was demonstrated that Ig requires antigen pro-
cessing by the antigen-presenting cells (APC) for the Id-peptide to
be presented on MHC class II molecules (Weiss and Bogen, 1989,
1991). Id-speciﬁc TCR transgenic T cells of this particular speci-
ﬁcity indeed help anti-Id B cells in the presence of Id+ Ig (Jacobsen
et al., 2010).
IDIOTYPIC NETWORK THEORY: ANTI-Id (Ab2) AS A
MIMICK OF ANTIGEN, AND AS INHIBITOR OF
PATHOGENIC AUTOANTIBODIES
The observation that Ig is autoimmunogenic paved the way for
the idiotypic network theory of Jerne (1974). Despite consid-
erable criticism of the network theory over the years, there is
much evidence to support an inﬂuence of Id in immune reg-
ulation – even though the mechanisms may not be exactly as
suggested by Jerne (1974). In particular, immunization with anti-
Id (Ab2) antibodies has been shown to induce anti-anti-Id (Ab3)
antibodies that can bind the “original” Ag, a feature they share
with Id+ (Ab1) antibodies. Thus, anti-Id antibodies may func-
tion as a mimic of antigen. This principle may be of practical
importance since antigens sometimes are poorly immunogenic,
or difﬁcult to obtain in sufﬁcient amounts for immunization. In
these cases, anti-Id monoclonal Ab (mAb) may be used as a sur-
rogate antigen for vaccination purposes. This strategy has recently
been successfully exploited by using anti-Id mAb as immuno-
gen for induction of anti-anti-Id Ab that bind gangliosides on
lung cancer (Hernandez et al., 2011) and melanoma (Ramos et al.,
2011) cells. Another interesting function of anti-Id Ab is that they
appear to block the function of pathogenic Id+ autoantibodies
as suggested in studies in type I diabetes (Oak et al., 2008). In
either case, technologies to increase immunogenicity of IgV region
antigenic determinants by immunization, as described herein, is
warranted.
IDIOTYPES AS TUMOR-SPECIFIC ANTIGENS
Another aspect of Id that has stood the test of time is their role as
a target on malignant B cells for an immune attack. Lynch et al.
(1972) found thatwhenmice immunizedwith Id+ M315myeloma
protein were later challenged with the Id+ MOPC315 plasmacy-
toma tumor cells, the mice were protected against tumor devel-
opment. Since plasmacytoma cells (an extramedullary form of
multiple myeloma) secrete copious amounts of the Id+ myeloma
protein, anti-Id antibodies should be blocked by omnipresent
myelomaprotein and appear not important for protection. Rather,
Id-speciﬁc CD4+ Th1 cells have been shown to kill the tumor
cells by a mechanism that involves IFNγ and tumor inﬁltrat-
ing M1 macrophages (Lauritzsen et al., 1994; Dembic et al., 2000;
Corthay et al., 2005, 2009; Haabeth et al., 2011). Immunotherapy
with anti-Id antibodies may be more important in B lymphomas
that secrete little Ig but that express high amounts of surface Ig as
targets for the anti-Id antibodies. Indeed, anti-Id antibodies have
a therapeutic effect against B lymphomas in experimental models
(George et al., 1987; Kaminski et al., 1987). However, phase III tri-
als in humans have been negative in two cases (Levy et al., 2008;
Freedman et al., 2009), while in a third study an improvement of
disease-free survival in patients vaccinated in ﬁrst remission was
observed (Schuster et al., 2011).
IDIOTYPES ARE WEAK ANTIGENS: CONVENTIONAL
AND NOVEL STRATEGIES TO INCREASE THEIR
IMMUNOGENICITY
As reviewed above, there are two important reasons for efﬁcient
induction of anti-Id immunity: (i) use of anti-anti-Id mAb (Ab2)
as mimic of antigen for vaccine purposes and (ii) induction of
Id-speciﬁc T cells and anti-Id antibodies in therapy of multiple
myeloma and Id+ B lymphomas. However, immunogenicity of
Ids is generally considered to be poor. The need for improving
the immunogenicity of Id-immunization is underscored by two
negative phase III trials on Id-vaccination of B lymphoma patients
(Levy et al., 2008; Freedman et al., 2009), while a third phase III
trial showed a marginal effect (Schuster et al., 2011). These trials
employed vaccination with Id-keyhole limpet hemocyanin (KLH)
conjugates and adjuvants.
The low immunogenicity of Id is probably related to B and T
cell tolerance, the levels of which may vary with various individ-
ual Ids. As long as the sole object of Id-vaccination is to obtain
anti-Id antibodies, and assuming that anti-Id B cells usually are
not tolerant, the problem of T cell tolerance can be circumvented
by conjugation of the Ig to a powerful carrier molecule, such as
KLH, that contain a multitude of T cell epitopes that should ﬁt
polymorphic MHC II molecules of most individuals (Kaminski
et al., 1987). Thus, Ig-KLH conjugates have become a “gold stan-
dard” for Id-vaccination of B lymphoma patients (Bendandi et al.,
1999; Inoges et al., 2006; Redfern et al., 2006; Levy et al., 2008;
Freedman et al., 2009; Timmerman et al., 2009; Schuster et al.,
2011). However, the “carrier strategy” does indeed not solve the
problem of lack of Id-speciﬁc T cell help – it just circumvents
it. Ig-KLH is commonly delivered with adjuvants that increase
the levels of anti-Id antibody responses. The empirical science of
adjuvants has developed considerably during the last decade, and
recent progress in the ﬁeld of receptors of innate immunity, such
as Toll-like receptors (TLRs), is likely to generate more power-
ful and clinically acceptable adjuvants. Given the poor effect of
Id-KLH vaccinations in phase III trials, immunization strategies
that elicit potent Id-speciﬁc T cells, and not only anti-Id antibod-
ies, might be desirable. Apart from the low efﬁcacy, the Id-KLH
strategy for Id-vaccination is labor intensive. Id-KLH vaccination
has for the most part been applied to patients with follicular B
cell lymphomas. These lymphomas arise from germinal center
B cells, and their B cell receptors (BCR) for antigen are usu-
ally marked by somatic mutations. Hence, lymphoma BCR of
different patients are different, and Id-vaccines have to be pre-
pared for each individual patient. Traditionally, this has involved
fusion between lymphoma cells and non-secreting myeloma cells
(rescue fusion) to obtain soluble lymphoma Ig for conjugation
with KLH (Schuster et al., 2011). More recently, recombinant
technologies have been applied to obtain lymphoma V region
DNA sequences, and to express these as Ig used for preparation
of Ig-KLH conjugates (Levy et al., 2008; Freedman et al., 2009).
These strategies for generation of individual patient-dedicated
protein Id-KLH vaccines are prohibitively time-consuming and
costly.
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There are a number of more recent innovative approaches to
improve Id-vaccination. In one approach, Id-speciﬁc immune
responses in mice could be enhanced by DNA vaccination with a
single-chain fragment variable (scFv)-bacterial antigen (fragment
C of tetanus toxin) fusion (King et al., 1998). In another approach,
Id was fused with lysosomal-associated membrane protein 1 (Id-
LAMP1), and integrated in recombinant vaccinia virus (rVV).
Dendritic cells (DCs) infected in vitro with Id-LAMP1 rVV were
used for immunization of mice, resulting in Id-speciﬁc T cell
responses and tumor protection (Muraro et al., 2005). In an APC-
targeting approach, but using protein rather than DNA, Id+ scFv
was fused with scFv speciﬁc for CD19 in a diabody format. Target-
ing of CD19 on B cells increased Id-speciﬁc responses (Ng et al.,
2012). Finally, B lymphoma cells were generated that by gene
targeting had their endogenous heavy (H) chain replaced by a
human H chain. Such engineered lymphoma cells were used to
immunize mice, and induced a T cell-mediated protection against
wild-type B cell lymphoma (Selmayr et al., 2000). These stud-
ies have contributed interesting approaches for Id-immunization,
but will not be discussed further as they are not examples of
APC-targeted DNA Id-vaccines, which is the theme of the present
paper.
In this review, it is considered that a combination of three ele-
ments could enhance Id-vaccination: (i) genetic construction of
patient-speciﬁc Id-vaccines, (ii) targeting of these to APC, and
(iii) delivery as DNA. Such a strategy could reduce the cost of
preparing individual vaccines and improve anti-Id responses, par-
ticularly Id-speciﬁc T cell responses. Of these three elements,
genetic construction of Id-vaccines, as well as delivery of Id-
vaccines as DNA, was already reported in the nineties (Hawkins
et al., 1993; Stevenson et al., 1995; Syrengelas et al., 1996; King et al.,
1998). APC-targeted DNA Id-vaccines is more recent (Biragyn
et al., 1999; Rufﬁni et al., 2004, 2010; Fredriksen et al., 2006;
Fredriksen and Bogen, 2007; Schjetne et al., 2007; Qin et al.,
2009;Froyland et al., 2011), and is the focus of the text to follow.
TARGETING ANTIGEN TO ANTIGEN-PRESENTING CELLS
INCREASES IMMUNE RESPONSES
Given the poor immunogenicity and labor-intensive production
of Id-vaccines, new vaccination strategies are warranted. It has
been known since the eighties that targeting of antigen to APC
increases both T and B cell responses (Kawamura and Berzofsky,
1986; Carayanniotis and Barber, 1987; Casten and Pierce, 1988;
Baiu et al., 1999). These pioneering studies were done by chemical
conjugation of antigen to antibodies speciﬁc for surface molecules
such as BCR,MHC II, FcR, and complement receptors (Kawamura
and Berzofsky, 1986; Carayanniotis and Barber, 1987; Baiu et al.,
1999) on APC. However, chemical conjugation often results in
different Ag:Ig ratios, therefore, chemical conjugates are fraught
with batch to batch variation. This problem is solved by genetic
fusion of antigen to APC-speciﬁc Ab, ensuring a deﬁned fusion
protein, as done by the authors and others in the late nineties
(Biragyn et al., 1999; Lunde et al., 1999, 2002). This recombinant
Ig strategy forAPChas becomevery popular, e.g., inwork targeting
surface molecules on DCs such as DEC205 (Hawiger et al., 2001;
Demangel et al., 2005; Kretschmer et al., 2006) andClec9a (Lahoud
et al., 2011).
APC-TARGETING OF T CELL EPITOPES INSERTED INTO THE
IMMUNOGLOBULIN STRUCTURE
Together with Sandlie, Lunde and Bogen developed a recombi-
nant Ig-based strategy for APC-targeting (Lunde et al., 1999). This
strategy was based on the observation, described above, that Ig are
endocytosed and processed by APC, and that CDR3 Id-peptides
are displayed on MHC class II molecules for recognition by Id-
speciﬁcCD4+ T cells (Bogen et al., 1986b;Weiss andBogen,1991).
Thus, if a CDR3 epitope could be excised from the Ig molecule
by the antigen processing machinery, T cell epitopes engineered
to replace loops between β-strands in constant (C) domains of
Ig molecules should also be excised for MHC-presentation. This
proved to be the case (Lunde et al., 1997). Laterworkdemonstrated
that many loops throughout the C-region, especially in the CH2
domain, are suited for T cell epitope replacement (Flobakk et al.,
2008). Indeed, multiple substitutions can be made within a single
Ig molecule, suggesting the possibility of using recombinant Ig for
multivaccine purposes (Rasmussen et al., 2012).
Importantly, since the T cell epitopes were inserted into the
C-domains, the original V regions should be dispensable and
therefore exchangeable withAPC-speciﬁcV regions cloned fromB
cell hybridomas of appropriate speciﬁcity. Such dual-substituted
recombinant Ig should target T cell epitopes to APC, resulting in
improved T cell responses. To test this idea, V regions speciﬁc for
IgD (Lunde et al., 1999; Rasmussen et al., 2001), MHC II (Lunde
et al., 2002), and CD40 (Schjetne et al., 2007) were exchanged with
originalV regions, and T cell epitopes were inserted into C domain
loops. Such APC-targeted recombinant Ig molecules, called Troy-
bodies, had an enhanced ability (×102–104) to stimulate CD4+ T
cell speciﬁc for model T cell epitopes (Lunde et al., 1999, 2002;
Rasmussen et al., 2001;Schjetne et al., 2007). A similar strategy was
later used by Hawiger et al. (2001), who genetically attached anti-
gen to theC-terminus of heavy chains of DC-speciﬁc anti-DEC205
mAb. This strategy has become popular and has been used with
minor variations in a large number of studies.
TARGETING OF Id IN A scFv FORMAT TO
ANTIGEN-PRESENTING CELLS
In 1996/1997, Bjarne Bogen had a sabbatical in the lab of Ron
Levy at Stanford University. This experience made it evident that
efﬁcient induction of anti-idiotypic antibodies was important for
immunotherapy of B lymphoma cells. In this respect, Troybodies
(see above) were deﬁcient because short Id-sequences introduced
into the Ig structure, although stimulatory for T cells, did not
generate conformational Id determinants recognized by B cells.
Another problem of Troybodies was that short Id-sequences only
would be presented by certain MHC molecules present in only a
fraction of individuals in the population.
A solution to these two problems seemed to be to include
patients’ B lymphoma V regions into an APC-targeted vaccine
molecule. This should allow induction of anti-idiotypic antibod-
ies and possibly also induction of Id-speciﬁc T cells. Such an
APC-targeted idiotypic vaccine should be bipolar, withAPC speci-
ﬁcity oriented in one direction and idiotypic V regions in the
other direction. Moreover, similar to IgG antibodies, the molecule
should be bivalent in order to increase avidity for APC. Bivalency
for idiotypic antigen should also be beneﬁcial, since bivalency
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would engender cross linking of BCR of anti-Id B cells, probably
inducing better anti-Id antibody responses. Finally, the molecule
should be devoid of Fc-associated biological effector functions
such as binding to Fc receptors and complement activation. This
statement may appear surprising since binding to Fc and comple-
ment receptors could indeed result in a positive outcome (Fearon
and Locksley, 1996). However, binding to such receptors could
potentially result in absorption of vaccine molecules and thereby
deviation from intended, optimalAPC targets, potentially blurring
the results.
HOMODIMERIC VACCINE MOLECULES THAT BIVALENTLY
TARGET DIMERIC IDIOTYPIC ANTIGEN TO APC
Based on the deliberations made above, the APC-targeted Id-
vaccine molecule was constructed as a homodimer, each chain of
the homodimer being composed of the following units: a target-
ing unit speciﬁc for APC, a homodimerization unit and Id antigen
expressed as scFv (Figure 1A). These unitswere connected by short
linkers (Figure 1B). Themolecules were genetically constructed by
use of a shuttle vector where the targeting units, the dimerization
unit and the Id scFv could be easily exchanged (Figure 1B). An
overview of published molecules used for Id-vaccination is given
in Table 1.
As for targeting units, the following have been published:
anti-mouse MHC class II as scFv (Fredriksen et al., 2006; Froy-
land et al., 2011), agonistic anti-mouse CD40 as scFv (Schjetne
et al., 2007), mouse MIP1α (CCL3) and RANTES (CCL5) bind-
ing CCR1,3,5 on APC (Fredriksen and Bogen, 2007), and human
MIP1α (LD78β; Rufﬁni et al., 2010). For all these targeting
units, negative controls not binding APC have been constructed,
such as scFv speciﬁc for the hapten NIP (Fredriksen et al., 2006;
Schjetne et al., 2007; Froyland et al., 2011), or chemokine versions
where the structural integrity has been destroyed by introduction
of a C11A mutation that disrupts a disulﬁde bond (Fredrik-
sen and Bogen, 2007; Rufﬁni et al., 2010). The scFv targeting
units have been expressed in the VH-VL order with mainte-
nance of speciﬁcity (an exception has been anti-TLR2, used in
other vaccine molecule studies not reviewed here, where rever-
sal of orientation to VL-VH improved binding to TLR2; Tunheim
et al., 2007). The different scFv used for targeting appeared to
inﬂuence the level of secretion of fusion protein, in the order
αNIP> αMHCII> αCD40. Concerning chemokines as targeting
moieties, different chemokines have been expressed approxi-
mately to the same levels in secreted homodimeric fusion proteins,
and maintained their binding characteristics and chemotactic
properties.
As for homodimerization motif, we have used a shortened
human γ3 Ig hinge with cysteines available for disulﬁde bond for-
mation. The shortened hinge has been connected via a G3S2G3SG
linker to human (γ3) or mouse (γ2b) CH3 domains that asso-
ciate non-covalently. Thus, the shortened hinge and the CH3
domain should confer homodimerization. Covalent dimerization
of proteins secreted by transfected HEK293 cells has been par-
tial, as estimated by SDS-PAGE under reducing or non-reducing
conditions, varying roughly from close to 100% homodimer-
ization to about 50%. Degree of covalent dimerization appears
to be inﬂuenced by targeting and antigenic units, but there are
also other factors involved. The degree of non-covalent homod-
imerization under physiological conditions has not yet been
tested.
As for idiotypic antigenswehaveused scFv315 (from theBALB/c
mouseplasmacytomaMOPC315; Eisen et al.,1968), scFvA20 (from
the BALB/c B cell lymphoma A20; Kim et al., 1979), and scFv of
four human multiple myeloma patients (Froyland et al., 2011).
ScFv have been in the VH-VL order, connected by a (G4S)3
linker. In general, we have experienced few if any problems in
expressing these various Id scFv as part of homodimeric vac-
cine proteins secreted by transiently transfected HEK293 cells. Id
scFv appeared to fold correctly in the vaccine molecule format
since they bound anti-Id mAb (Fredriksen et al., 2006; Fredrik-
sen and Bogen, 2007; Schjetne et al., 2007; Rufﬁni et al., 2010;
Froyland et al., 2011).
TARGETED IDIOTYPIC VACCINE, TESTED AS PROTEINS,
ENHANCE T AND B CELL RESPONSES
Both anti-MHCII-scFv315 and MIP-1α–scFv315 proteins were
about ×1,000-fold more effective, on a molar basis, at stimulat-
ing Id-speciﬁc CD4+ T cells from Id315-speciﬁc TCR-transgenic
mice (Fredriksen et al., 2006; Fredriksen and Bogen, 2007). These
results are highly promising for in vivo immunization with pro-
teins. Unfortunately, it has until nowbeen cumbersome toproduce
sufﬁcient amounts of puriﬁed vaccine proteins from transiently
transfected HEK293 and stably transfected NS0 cells for extensive
immunization experiments. However, a single injection of 100 μg
of MIP-1α–scFv315 vaccine proteins in PBS induced a 20% protec-
tion against a challengewithMOPC315 plasmacytoma cells on day
14 after immunization, compared to nil protection obtained with
the non-targeted control (Fredriksen and Bogen, 2007). These
results are encouraging, but more efﬁcient protein production is
needed for extensive investigations on protein vaccination to be
carried out.
DELIVERY OF APC-TARGETED Id AS DNA VACCINES INDUCE
STRONG ANTI-Id RESPONSES AND TUMOR PROTECTION
Given the problems in producing sufﬁcient proteins for immu-
nization, we resorted to perform DNA immunization. The
rationale for this choice was the previous ﬁnding that Ig H and
L chain genes, when injected intramuscularly, resulted in pro-
longed production of assembled and functional H + L mAb
molecules that could be detected in serum (Tjelle et al., 2004).
Production of mAb by muscle cells was dependent upon elec-
troporation of the injection site, which enhances the number of
DNA-transfected cells (Mathiesen, 1999), and thus protein pro-
duction and secretion. The particular mAb produced and secreted
by muscle, anti-MHC II (I-Ed) could be detected in serum of a
mouse that lacked I-Ed but not in a mouse that expressed I-Ed.
Thus, muscle-produced mAb bound MHC II molecules in vivo
(Tjelle et al., 2004).
On this basis,we considered it possible that injectionof homod-
imeric vaccine plasmid, combined with electroporation, could
result in secretion of vaccine fusion protein into extracellular ﬂuid,
followed by binding to surface molecules on APC. Experiments
to test this were ﬁrst done with anti-MHCII-scFv315 plasmid,
using anti-NIP-scFv315 as non-targeted control (Fredriksen et al.,
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FIGURE 1 | Design, construction, and DNA delivery of APC-targeted
vaccines. (A)The vaccine proteins are heterodimers. Each chain is composed
of an N-terminal targeting unit [scFv(VL + VH) or chemokines, violet ], that
bind surface receptors on APC, a dimerization unit composed of a shortened
human Ig hinge and CH3 domain (blue), and an antigenic unit corresponding
to tumor-speciﬁc scFv from a B cell tumor (multiple myeloma, B cell
lymphoma; red ). As non-targeted controls we used vaccine molecule
versions where the targeting unit was replaced with either scFv speciﬁc for
the hapten NIP, or inactive (mutated) chemokine. (B) Gene construct. The
targeting unit is inserted into the V cassette of the pLNOH2 vector. The
dimerization unit, composed of h1 and h4 hinge exons and the CH3 exon of
human IgG3 (blue), is linked to the antigenic unit (red ) and inserted together
in the C cassette of pLNOH2. The (G4S)3 linkers (orange) and the GLSGL
linker (green) are indicated. The gene is expressed from a CMV promoter
(hatched) and a leader sequence (striated ) of the pLNOH2 vector (uncolored ).
Upstream of h1 is an intronic sequence (light gray ) Reproduced with
modiﬁcations from Mol. Ther. 13: 776–785, 2006, with permission from the
publisher. (C)Transfected cells secrete vaccine proteins that target antigen
presenting cells. The APC travels to the draining lymph node where it meets
CD4+ T cells, B cells and CD8+ T cells.
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Table 1 | Efficiency of various targeting units in APC-targeted Id-vaccines*.
Mouse αMHC class II
(Fredriksen et al., 2006;
Froyland et al., 2011)
Mouse αCD40
(Schjetne et al.,
2007)
Mouse MIP-1α
(Fredriksen and
Bogen, 2007)¤
Human MIP-1α
(Ruffini et al.,
2010)
Mouse RANTES
(Fredriksen and
Bogen, 2007)¤
CD4+ T cell responses in vitro ++ ++ (+) +++ ++ ++(+)
CD4+ T cell responses in vivo +++ ++ +++ n.t. ++
Anti-Id antibody responses +++ ++ ++ ++ +
Protection against Id+ tumors 60% 50–60% 70–80%# n.t. 40–50%
*Responses are qualitatively evaluated +++, ++, + compared to non-targeted controls. Since side by side comparisons were not done, and results were published
separately (except MIP-1α and RANTES), exact comparison is impossible. The indicated refs should be consulted for details. Id-speciﬁc responses were mostly
tested with scFv from the MOPC315 mouse myeloma, but also with scFv from the mouse A20 B lymphoma. In one study (Froyland et al., 2011) human MM scFv from
4 patients were tested. The results refer to vaccine molecules with a human dimerization motif (shortened hinge + CH3). For the reference marked with ¤ besides
the ref, equivalent mouse dimerization motif was tested in parallel (see also Figure 2).
#Antibody depletion experiments indicated that CD8+ T cells conferred most of the protection against MOPC315 MM cells.
n.t., not tested.
2006). The results demonstrated that electroporation was needed
to detect vaccine proteins in serum. Moreover, anti-MHC II (I-
Ed) vaccine proteins were detected in mice lacking I-Ed but were
absent in mice expressing I-Ed, consistent with absorption on
MHC II+ APC. These results led to amodel for how targetedDNA
vaccines work. Brieﬂy, transfected cells secrete vaccine protein that
target APC, followed by drainage to lymph nodes for initiation of
T and B cell responses (Figure 1C). The distinction from conven-
tional DNA immunization, where the transfected cells themselves
are thought to serve as APC, is evident.
Next, induction of anti-Id antibodies in serum was followed
(Fredriksen et al., 2006). Anti-MHC II-scFv315 induced a strong
and rapid anti-idiotypic antibody response compared to non-
targeted (anti-NIP) control. One immunization was sufﬁcient for
detection of anti-Id antibodies within 14 days. Antibody levels
increased to day 60, then declined until day 170. Three immu-
nizations spaced 21 days apart, increased antibody levels. A DNA
dose-sparing effect of targeting was observed. These results were
encouraging since M315 protein is poorly immunogenic and pro-
longed immunization schedules have been required to elicit anti-Id
antibody responses.
Concerning in vivo T cell responses, MHC II-targeted DNA
immunization was 100–1,000 times better at stimulation of
Id-speciﬁc CD4+ T cells, as revealed by immunizing TCR-
transgenic mice and BrdU incorporation experiments (Fredriksen
et al., 2006).
As for resistance to tumor challenge,mice immunizedoncewith
anti-MHC II-scFv315 resisted a challenge with MOPC315 tumor
cells while control mice immunized with non-targeted control
were not protected. Similar results were obtained with DNA vac-
cines constructed for BALB/c B lymphomaA20,where vaccination
also induced tumor resistance.
EXTENSION TO OTHER TARGETING UNITS
Two other mouse targeting units have been published: agonis-
tic scFvαCD40 based on the agonistic anti-CD40 mAb FGK45
(Schjetne et al., 2007) and the mouse chemokines MIP-1α and
RANTES (Fredriksen and Bogen, 2007). The former was indeed
selected because agonistic targeting of CD40 could serve two
functions: (i) activation of APC and (ii) loading with Id-
peptide. Both effects were shown to be induced by vaccine
molecules (Schjetne et al., 2007). Immunization with scFvαCD40–
scFv315DNA vaccines induced anti-Id antibodies and protection
against tumor challenge.
MIP-1α andRANTESwere selected because they are inﬂamma-
tory chemokines and because previous experiments performed
in our laboratory in surrogate systems employing mAbs to
chemokine receptors had indicated that CCR1, 3, and 5 (to
which MIP-1α and RANTES bind) could be promising targets
(Schjetne et al., 2003). Moreover, chemotactic activity could cause
APC to accumulate at site of injection, resulting in enhanced
vaccine uptake and presentation. MIP-1α performed better than
RANTES in assays for chemotaxis, induction of anti-Id antibodies
and tumor protection. These results of the efﬁcacy of the various
targeting units are summarized in Table 1.
It should be emphasized that genetic fusion of other
chemokines (MIP-3α and MCP3) to scFvId has previously been
successfully used as DNA vaccines by Biragyn and Kwak in A20,
38C13, andMOPC315 mouse tumor models (Biragyn et al., 1999;
Rufﬁni et al., 2004; Qin et al., 2009; see below). In these studies,
the fusion proteins had a monomeric form where the chemokine
moiety was directly attached to scFv. Interestingly, when the
chemokine-scFv DNA vaccine was combined with myotoxins
that induce sterile inﬂammation with recruitment of APC at the
intramuscular injection site, enhanced antitumor immunity was
observed (Qin et al., 2009).
BIVALENCY AND XENOGENEIC SEQUENCES INCREASE
IMMUNOGENICITY OF TARGETED BIVALENT IDIOTYPIC
VACCINES
A comparison was done between bivalent and monovalent Id
fusion protein with MIP-1α as targeting unit. The monovalent
form was constructed ad modum Biragyn and Kwak, where the
chemokine is directly attached to idiotypic scFv (Biragyn et al.,
1999). Compared on a molar basis, the bivalent form had a higher
chemotactic activity both in vitro and in vivo, was more efﬁcient at
stimulation of T cells in vitro and in vivo, had an increased ability
to induce anti-Id antibodies, and induced a higher resistance to
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tumor challenge. Thus, bivalency appeared to increase efﬁcacy
of the vaccine molecule in a variety of short-term and long-term
assays in vitro and in vivo (Figure 2). Amajor part of the enhanced
efﬁciency is likely to be due to bivalency of the targeting unit
MIP-1α, and hence enhanced chemotactic activity and binding
to APC.
A side by side comparison of vaccine molecules having human
(γ3) or mouse (γ2b) CH3 domains was undertaken, using MIP-
1α-targeted vaccine molecules. While no inﬂuence was seen in
short-term assays, such as chemotaxis or stimulation of Id-speciﬁc
T cells in vitro or in vivo, a clear inﬂuence was observed in
long-term in vivo assays such as induction of antibodies and resis-
tance to an Id+ tumor challenge (Fredriksen and Bogen, 2007;
Figure 2). Thus, xenogeneic sequences in the homodimerization
domain appeared to increase immunogenicity. However, vaccine
constructs with mouse γ2b homodimerization domain appear to
be less well secreted by transfected cells in vitro. If this is also
the case upon DNA vaccination and electroporation, i.e., that
transfected cells in vivo produce less vaccine protein, this could
have contributed to the decreased immunogenicity of mouse
γ2b-containing DNA vaccines. A possible explanation for these
ﬁndings could be that xenogeneic CH3 sequences are presented on
MHC class II molecules. Xenogeneic sequences might be required
for generation of sufﬁcient help, since the T cell repertoire for
syngeneic V regions is purged of T cells responding to germline–
encoded sequences and is limited to recognition of Id-peptides
expressing somatic mutations or V(D)J junctional sequences
(Bogen et al., 1985, 1986a,b, 1993; Eyerman and Wysocki, 1994;
Eyerman et al., 1996) reviewed in Bogen and Rufﬁni (2009).
This explanation is consistent with the contribution of KLH
to immunogenicity of Id in Id-KLH conjugates, by induction
of KLH-speciﬁc T helper cells. Based on such results one may
envisage that deliberate insertion of foreign promiscuous T cell
epitopes, with ability to bind most MHC molecules in the species,
could increase efﬁciency of the targeted vaccine molecules.
TARGETING SPECIFICITY INFLUENCES PHENOTYPE OF
ELICITED IMMUNE RESPONSES
It is clearly of great importance to be able to direct the type of anti-
Id immune responses elicited by Id-vaccination. For example, in
B cell lymphoma, anti-Id antibodies appear to be important for
tumor eradication (Syrengelas and Levy, 1999), while in multiple
myeloma, Id-speciﬁc T cells seems to be the therapeutically most
important arm of Id-immunity (Lauritzsen et al., 1994; Dembic
et al., 2000; Corthay et al., 2005; Haabeth et al., 2011). Thus, Id-
vaccines should elicit the kind of immune response suitable for
the particular B cell tumor disease of the patient. Steering the phe-
notype of Id-immunity in the desired directionmight be obtained
by varying the targeting units of the bivalent idiotypic vaccine
molecule. This has not yet been investigated fully, but available
data suggest that targeting of Id-vaccines with scFvαMHC class II
induces high amounts of antibodies while targeting with MIP-
1α induces more T cells (Fredriksen et al., 2006; Fredriksen and
Bogen, 2007). It might be of particular merit to target particular
subsets of APC, i.e., CD8+ DCs, the latter being known for their
ability to cross present antigen to cytotoxic CD8 T cells.
FIGURE 2 | Bivalency and xenogeneic sequences increase
immunogenicity of vaccine molecules. Homodimers with human
xenogeneic dimerization motifs were compared with homodimers with
murine syngeneic dimerization motifs and monomers for induction of
chemotaxis, Id-speciﬁc T and B cell responses, and protection
against Id+ tumor challenge. Vaccine molecules had MIP1-α as
targeting unit and scFv315 or scFvA20 as antigenic unit (Fredriksen and
Bogen, 2007).
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A HYPOTHETICAL MODEL FOR ACTION OF APC-TARGETED
BIVALENT VACCINE MOLECULES
The mechanism for why targeted vaccine molecules (called vac-
cibodies) improve T and B cell responses to Id is hypothesized
in Figure 3. Brieﬂy, targeting of vaccine molecules to APC such
as DCs should result in efﬁcient stimulation of CD4+ T cells.
Simultaneously, B cells should bind conformational determinants
on the antigenic units, and process and present the antigen on
their MHC class II molecules. Primed B cells will receive help
from the CD4+ T cells already stimulated by DCs, resulting in
generation of plasma cells and antibody production. In addition,
certain targeting units, such as MIP-1α, may by unknown mecha-
nisms result in cross-presentation of Id onMHC class I molecules
FIGURE 3 | Proposed mechanism for howAPC-targeted homodimeric
vaccine molecules efficiently stimulate bothT and B cell responses.
(A) (i) Vaccibodies bind to surface molecules on APC, such as dendritic cells
and induce their maturation. (ii) Vaccibodies are processed and peptides
from the antigenic unit are presented on MHC class II molecules of APC to
naïve CD4+ T cells that become effector T cells. (iii) B cells with a B cell
receptor (BCR)-speciﬁc for conformational determinants on complete
vaccibodies internalize vaccibodies; process them, and present antigenic
peptides on their MHC class II molecules to the effector CD4+ T cells. (iv)
B cells receive help from the effector CD4+ T cells and develop into plasma
cells that secrete antibodies. Finally, antigen-speciﬁc antibodies and CD4+
T cells cause the elimination of the antigen. (v) Vaccibodies with certain
targeting units (MIP-1α) can induce presentation on MHC class I, and
cross-priming of CD8+ T cells is thought to be particularly important for
viral infections and cancer. (B) A variant model where homodimeric vaccine
molecules bridge APC and B cells, resulting in a “tug of war” for antigen. T
cell could interact with MHC II-Ag complexes on both APC and B cells, as
indicated.
and generation of CD8+ T cells (Fredriksen and Bogen, 2007;
Figure 3A). A variant model may be considered where the vac-
cine molecules could bridge DCs and B cells, as in an APC B cell
synapse (Batista et al., 2001). A “tug of war” between the APC
and the B cell could result in Ag being displayed as peptides on
MHC II molecules of both cells (Figure 3B). CD4+ T cells could
interact with both the APC and the B cell, either consecutively or
simultaneously, in the latter case forming a three-member cellular
complex.
EXTENSION TO HUMAN TARGETING UNITS AND HUMAN
IDIOTYPES FROM PATIENTS
Homologous chemokines are expressed in mouse and man and
indeed most mammal species. Therefore, since mouse MIP-1α
gave encouraging results in mice (Fredriksen and Bogen, 2007),
it was of particular interest to test if human MIP-1α could also
function as a targeting unit. Moreover, if human MIP-1α bound
to mouse chemokine receptors, a vaccine intended for human use
could ﬁrst be tested in mice prior to human application. Such
studies could pave the way for application of APC-targeted Id-
vaccines in humans.
In humans, there are two homologs of MIP-1α, LD78α and
LD78β both sharing 74% homology with the mouse MIP-1α. The
two variants are 96%homologous, however,while LD78α-targeted
vaccine was unable to bind strongly to both murine and human
chemokine receptors, LD78β-fusion vaccines bind both murine,
human and macaque chemokine receptors. Furthermore, LD78β-
targeted vaccines demonstrated increased ability to activate CD4+
T cells and antigen-speciﬁc antibodies in mice models (Rufﬁni
et al., 2010). Thus, the human vaccine product can be tested for
functionality in both murine and non-human primate models
before entering the clinic.
The overall aim of the studies reviewed herein is to develop
Id-vaccines that work in patients. We therefore genetically con-
structed scFv from multiple myeloma cells obtained from bone
marrow of four patients, and inserted these into vaccinemolecules
speciﬁc for mouse MHC II (I-Ed; Fredriksen et al., 2006). Mice
DNA-immunized with these constructs produced antibodies that
in ELISA bound the particular puriﬁed serum myeloma pro-
tein corresponding to the scFv used, but poorly or not at all
to myeloma proteins from the other three patients. By this cri-
terium, the scFv must correctly fold when produced and secreted
by transfected mouse cells. Anti-idiotypic antibody titers were
much higher in mice immunized with MHC II-targeted vaccine
constructs compared with the non-targeted (NIP-speciﬁc) con-
trol (Fredriksen et al., 2006). The anti-idiotypic antibodies could
be used to establish ELISAs speciﬁc for the myeloma protein of
each patient (Froyland et al., 2011). These ELISAs were about 100-
foldmore sensitive than standard immunoﬁxation for detection of
myeloma protein in serum, and could be used for early detection
of recurrence of disease.
FUTURE PERSPECTIVES: EXTENSION TO VACCINATION OF
HUMANS WITH B CELL CANCERS
As reviewed above, scFv can be constructed from patients with
B cell malignancies, and inserted into targeted bivalent DNA
vaccines (Froyland et al., 2011). The ease and rapidity with
Frontiers in Oncology | Tumor Immunity October 2012 | Volume 2 | Article 154 | 8
“fonc-02-00154” — 2012/10/28 — 19:17 — page 9 — #9
Fredriksen et al. Targeted DNA vaccines for Id-responses
which the vaccines can be genetically constructed and pro-
duced as DNA are clear advantages for generation of individual
patient-speciﬁc Id-vaccines. Mice immunized with MHC II-
targeted constructs make anti-Id antibodies to human Id after a
single DNA injection combined with electroporation (Froyland
et al., 2011).
In future work, we plan to equip patient-speciﬁc scFvDNAvac-
cines with targeting units speciﬁc for human APC. Provided the
targeting unit cross-react between human and mouse APC, which
is the case for human MIP-1α (LD78β; see above), the DNA vac-
cine intended for human use can be tested in mice prior to human
application. It should be noted that DNA vaccination with elec-
troporation has been performed in humans without serious side
effects (van Drunen Littel-van den Hurk and Hannaman, 2010;
Vasan et al., 2011). However, the DNA vaccines tested so far have
been of a non-targeted nature. In our long-term experiments in
mice,we have yet to observe any detrimental side effects of targeted
DNA vaccines.
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